Oncobiologics (OTLK)
(Delayed Data from NSDQ)
$8.43 USD
+0.24 (2.93%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.42 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
OTLK 8.43 +0.24(2.93%)
Will OTLK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for OTLK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OTLK
All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
OTLK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More
Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate
Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings?
Other News for OTLK
Outlook Therapeutics files to sell 2.78M shares of common stock for holders
Outlook Therapeutics files to sell 2.78M shares of common stock for holders
Four new option listings on April 17th
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential